Vicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $16.60 on Friday. The firm has a market capitalization of $2.31 billion, a P/E ratio of -15.37 and a beta of 1.33. Denali Therapeutics Inc. has a 1-year low of $15.45 and a 1-year high of $33.31. The business’s 50-day simple moving average is $19.26 and its 200-day simple moving average is $19.25.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period last year, the business earned ($0.75) earnings per share. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DNLI has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Denali Therapeutics in a research note on Wednesday, February 28th. UBS Group decreased their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. The Goldman Sachs Group decreased their price target on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Finally, HC Wainwright decreased their price target on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $41.22.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its holdings in shares of Denali Therapeutics by 85.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock valued at $46,000 after buying an additional 768 shares during the period. CWM LLC raised its holdings in shares of Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the period. Assetmark Inc. raised its holdings in shares of Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the period. KBC Group NV purchased a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $53,000. Finally, Sandia Investment Management LP purchased a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $70,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.